Topics

Amgen Announces Phase 3 Multiple Myeloma Study of Kyprolis Plus Darzalex Meets Primary Endpoint of Progression-Free Survival

09:49 EDT 13 Sep 2019 | Speciality Pharma Journal

THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival (PFS). The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed …

Original Article: Amgen Announces Phase 3 Multiple Myeloma Study of Kyprolis Plus Darzalex Meets Primary Endpoint of Progression-Free Survival

NEXT ARTICLE

More From BioPortfolio on "Amgen Announces Phase 3 Multiple Myeloma Study of Kyprolis Plus Darzalex Meets Primary Endpoint of Progression-Free Survival"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...